Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
ABBVIE INC. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 149.28 USD | +0.89% | +4.09% | -7.63% | |
| Dec. 08 | Health Care Climbs as Deal Wave Seen Continuing -- Health Care Roundup | DJ |
| Dec. 08 | S&P 500 Rises for Sixth Straight Week as Focus Shifts to Fed Meeting, Inflation Data | MT |
ETFs positioned on AbbVie Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 8.73% | 3,593 M€ | -3.99% | ||
| 7.12% | 6 M€ | -6.18% | - | |
| 6.86% | 18 M€ | -7.62% | - | |
| 6.85% | 26 M€ | +10.39% | - | |
| 6.48% | 9,170 M€ | -3.96% | ||
| 6.41% | 124 M€ | -5.01% | ||
| 6.41% | 126 M€ | -4.35% | ||
| 6.26% | 13 M€ | -31.59% | ||
| 6.26% | 2 M€ | 0.00% | ||
| 6.24% | 16 M€ | 0.00% | - | |
| 5.92% | 1 M€ | -.--% | ||
| 5.92% | 1 M€ | -5.93% | ||
| 5.92% | 28 M€ | -11.58% | - | |
| 5.92% | 38 M€ | -8.77% | ||
| 5.64% | 232 M€ | -8.36% | ||
| 5.30% | 16 M€ | 0.00% | - | |
| 5.30% | 132 M€ | -7.59% | - | |
| 5.30% | 27 M€ | -6.00% | - | |
| 5.29% | 12 M€ | -6.32% | - | |
| 5.29% | 1 M€ | -.--% | - | |
| 5.29% | 50 M€ | -6.86% | - | |
| 5.26% | 91 M€ | +0.84% | ||
| 5.26% | 5 M€ | +0.62% | - | |
| 5.24% | 362 M€ | +0.89% | ||
| 5.23% | 309 M€ | -1.87% | ||
| 5.23% | 2 M€ | -3.16% | - | |
| 5.22% | 1,872 M€ | -.--% | ||
| 5.22% | 105 M€ | -4.86% | - | |
| 5.22% | 33,985 M€ | -2.78% | ||
| 5.15% | 8 M€ | 0.00% | - | |
| 4.99% | 33 M€ | -3.06% | ||
| 4.99% | 892 M€ | 0.00% | ||
| 4.97% | 2,705 M€ | -2.72% | ||
| 4.92% | 992 M€ | -7.09% | - | |
| 4.90% | 11 M€ | 0.00% | - | |
| 4.90% | 820 M€ | -4.99% | - | |
| 4.90% | 68 M€ | 0.00% | - |
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (78.7%), Germany (2.3%), Canada (2%), Japan (1.6%), China (1.6%), France (1.4%), Australia (0.9%), Spain (0.9%), the United Kingdom (0.8%), Italy (0.8%), Brazil (0.7%) and other (8.3%).
Sector
Pharmaceuticals
Calendar
2024-01-11
- U.S. Currency
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
149.28USD
Average target price
167.53USD
Spread / Average Target
+12.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.63% | 264 B $ | |
| +63.47% | 538 B $ | |
| +42.56% | 430 B $ | |
| -12.58% | 372 B $ | |
| -6.49% | 263 B $ | |
| -12.81% | 232 B $ | |
| +1.35% | 198 B $ | |
| -9.77% | 197 B $ | |
| -43.83% | 163 B $ | |
| +2.47% | 144 B $ |
- Stock
- Equities
- Stock AbbVie Inc. - Nyse
- Funds and ETFs AbbVie Inc.
